Loading...
•
Jun 30
Zura Bio Q2 2025 Earnings Report
Zura Bio reported a net loss with higher R&D and G&A expenses in Q2 2025.
Key Takeaways
Zura Bio posted a net loss of $15.993 million in Q2 2025 as the company continued to invest in Phase 2 trials for tibulizumab. R&D and G&A expenses rose significantly year-over-year, while the company maintained a strong cash position.
Cash and cash equivalents totaled $154.5 million, expected to fund operations through 2027.
R&D expenses increased to $8.704 million, driven by Phase 2 trial activities.
G&A expenses rose to $9.358 million, reflecting organizational expansion.
Net loss was $15.993 million or $0.17 per share.
Zura Bio
Zura Bio
Forward Guidance
Zura Bio expects current cash to fund operations through 2027 and continues to advance clinical trials for tibulizumab.
Positive Outlook
- Initiated global Phase 2 study (TibuSHIELD) for hidradenitis suppurativa.
- Continued progress in systemic sclerosis Phase 2 study (TibuSURE).
- Strong cash position of $154.5 million.
- Appointment of new CFO and board member to strengthen leadership.
- No immediate need for fundraising through 2027.
Challenges Ahead
- Increased R&D expenses due to trial advancement.
- G&A costs rose with organizational expansion.
- No revenue generated this quarter.
- Net loss widened to $16 million.
- Stock dilution evident from increased outstanding shares.